Undetectable equals Untransmittable (“U=U”) is a message that conveys no risk of sexual transmission when people living with HIV (PLHIV) have a viral load (VL) <200 HIV RNA copies per milliliter of blood (cp/mL). VL assays that use dried blood spots (DBS) have a minimum detection threshold of 700-839 cp/mL, in contrast to VL assays that use plasma which can detect <200 cp/mL. Because some countries rely on DBS-based VL testing that is unable to detect the U=U threshold of <200 cp/mL, some providers are reluctant to adopt U=U messaging, especially in areas where plasma VL assays are not universally available. To address this potential barrier, we assessed the proportion of those with VL <200 cp/mL among PLHIV participants with VL <1000 cp/mL and were taking antiretroviral therapy (ART).
We conducted a pooled multi-country secondary data analysis using complex survey design and weights of the 2015-2018 cross-sectional Population-based HIV Impact Assessments (PHIA) in six sub-Saharan African countries. Inclusion criteria were: adults aged 15-59 years who tested HIV-positive in the PHIA surveys; on ART, defined as detectable antiretrovirals and/or self-report of current ART use; and available plasma VL results. Of the HIV-positive adults on ART who had a VL <1000 cp/mL (World Health Organization’s definition of viral load suppression (VLS)), we calculated the proportion who met the U=U cutoff of <200 cp/mL. .
Overall, of the 8,031 HIV-positive adults on ART, 86.9% (95% confidence interval (CI) 86.4-87.4) had a VL <1000 cp/mL. Of the 7,003 participants on ART with a VL <1000 cp/mL, 95.1% (95% CI 94.7-95.4) had a VL <200 cp/mL. Of the 4,970 participants with a VL <1000 cp/mL who were on ART and self-reported current ART for ≥12 months, the proportion with VL <200 cp/mL was 96.6% (95% CI 96.2-96.9).
These nationally representative population-based data demonstrate that a very high proportion of all HIV-positive adults on ART with VL <1000 cp/mL also had VL <200 cp/mL, suggesting that U=U messaging may be suitable even in settings limited to DBS-based VL measures. With continued ART adherence and high-quality laboratory sample collection and systems to verify VLS, PHIA data supports that the scale-up of U=U messaging may be appropriate regardless of which VL testing platform is available.